ocugen inc nasdaq ocgn is trading higher tuesday after a company 8k showed it entered into a development and commercial supply agreement with bharat biotech pursuant to which bharat biotech will exclusively manufacture and supply the company with its requirements of covaxin clinical trial materials as well as manufacture and supply covaxin drug product components the world health organization is set to decide on the emergency use listing authorization of covaxin today covaxin is indias indigenouslydeveloped covid19 vaccine in collaboration with ocugen ocugen is a clinicalstage biopharmaceutical company it is focused on discovering developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases ocgn price action ocugen has traded as high as 1877 and as low as 25 cents over a 52week period the stock was up 622 at 717 at time of publication